Natera Announces the Appointment of Michael C. Little as Senior Vice President, R&D
SAN CARLOS, Calif., Dec. 4, 2015 /PRNewswire/ — Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Michael C. Little, Ph.D. has joined the company as Senior Vice President, Research and Development. Prior to Natera, Dr. Little was the Global Head of Diagnostics Development at Novartis. During his tenure, Dr. Little managed the diagnostic development of all molecular diagnostic programs, as well as oncology and general medicine companion diagnostic programs. Previously, Dr. Little served as Vice President, R&D, Medical Affairs, Regulatory & Scientific Affairs, and Program Management at Novartis Diagnostics.
Dr. Little holds a Ph.D. in Microbiology, and has over 27 years’ experience in biotech and diagnostics research and commercialization. His organizations have comprised chemistry, engineering, bioinformatics, pathology, kit manufacturing, program management functions, quality control and regulatory affairs.
"We are delighted to welcome Mike to Natera where he will leverage his deep experience managing large numbers of complex diagnostics projects," said Matthew Rabinowitz, Ph.D., CEO of Natera. "Mike will lead our R&D team’s product development efforts and strategic planning, particularly as it relates to the evolving regulatory landscape."
Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum™ pre-implantation genetic test for embryo selection during IVF; the Anora™ miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama™ non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.
Mike Brophy, Investor Relations, 650-249-9091 x 1471
Michael Hromadik, Media Relations, 858-442-2215
SOURCE Natera, Inc.